Literature DB >> 18221954

Prognostic value of MET, RON and histoprognostic factors for urothelial carcinoma in the upper urinary tract.

E Compérat1, M Roupret, E Chartier-Kastler, M O Bitker, F Richard, P Camparo, F Capron, O Cussenot.   

Abstract

PURPOSE: RON (recepteur d'origine Nantais) (Santa Cruz Technology, Santa Cruz, California) and c-met (Dako, Glostrup, Denmark) are members of the c-met proto-oncogene family. c-met encodes a receptor tyrosine kinase and has a role in oncogenesis. RON has a role in cell transformation and epithelial tumorigenesis. Over expression of the 2 genes has been demonstrated in human bladder cancer. We explored whether over expression of the 2 proteins has a role in the tumorigenesis and defined histoprognostic factors of poor clinical outcomes in patients with these tumors.
MATERIALS AND METHODS: We reviewed the records of 42 patients with upper urinary tract urothelial carcinoma. A total of 24 tumors were localized in the renal pelvis and 18 were in the ureter. Immunohistochemical staining for RON and c-met was performed using tissue microarrays.
RESULTS: Patient age was 46 to 100 years (mean 70.6). Of the patients 23 (54%) died of disease. Over expression of c-met was associated with a higher risk of embolism (p = 0.0002), while over expression of RON was not significantly associated with emboli (p = 0.5). Univariate analysis showed that relapse was significantly associated with ureteral localization (p = 0.02), vascular invasion (p = 0.003), and high grade (p = 0.04) and high stage (0.02) urothelial carcinoma. The association with vascular invasion, and high grade and high stage urothelial carcinoma was also statistically significant (p <0.0001). Notably superficial tumors showed an important relapse rate (p = 0.003).
CONCLUSIONS: Independent prognostic factors of relapse in upper urinary tract urothelial carcinoma are ureteral localization, vascular invasion, high grade and high stage. c-met seems to influence the development of vascular invasion via an unknown mechanism. Nevertheless, to our knowledge an association between c-met over expression and aggressive clinical behavior in upper urinary tract carcinomas has not been previously reported.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18221954     DOI: 10.1016/j.juro.2007.10.079

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

1.  Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.

Authors:  Zhenfu Han; Peter K W Harris; Darin E Jones; Ryan Chugani; Tommy Kim; Manjula Agarwal; Wei Shen; Scott A Wildman; James W Janetka
Journal:  ACS Med Chem Lett       Date:  2014-10-09       Impact factor: 4.345

Review 2.  MSP-RON signalling in cancer: pathogenesis and therapeutic potential.

Authors:  Hang-Ping Yao; Yong-Qing Zhou; Ruiwen Zhang; Ming-Hai Wang
Journal:  Nat Rev Cancer       Date:  2013-07       Impact factor: 60.716

Review 3.  Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets.

Authors:  Katherine Chang; Anand Karnad; Shujie Zhao; James W Freeman
Journal:  Oncotarget       Date:  2015-02-28

4.  Predictive value of clinicopathological markers for the metachronous bladder cancer and prognosis of upper tract urothelial carcinoma.

Authors:  Chenchen Feng; Lujia Wang; Guanxiong Ding; Qiang Ding; Zhongwen Zhou; Haowen Jiang; Zhong Wu
Journal:  Sci Rep       Date:  2014-02-06       Impact factor: 4.379

5.  Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder.

Authors:  Brian K McNeil; Maximiliano Sorbellini; Robert L Grubb; Andrea Apolo; Fabiola Cecchi; Gagani Athauda; Benjamin Cohen; Alessio Giubellino; Haley Simpson; Piyush K Agarwal; Jonathan Coleman; Robert H Getzenberg; George J Netto; Joanna Shih; W Marston Linehan; Peter A Pinto; Donald P Bottaro
Journal:  J Transl Med       Date:  2014-10-21       Impact factor: 5.531

Review 6.  Met in urological cancers.

Authors:  Yasuyoshi Miyata; Akihiro Asai; Kensuke Mitsunari; Tomohiro Matsuo; Kojiro Ohba; Yasushi Mochizuki; Hideki Sakai
Journal:  Cancers (Basel)       Date:  2014-12-16       Impact factor: 6.639

7.  Expression of Estrogen Receptor Beta Predicts Oncologic Outcome of pT3 Upper Urinary Tract Urothelial Carcinoma Better Than Aggressive Pathological Features.

Authors:  Hao Lun Luo; Ming Tse Sung; Eing Mei Tsai; Chang Shen Lin; Nai Lun Lee; Yueh-Hua Chung; Po Hui Chiang
Journal:  Sci Rep       Date:  2016-04-07       Impact factor: 4.379

Review 8.  Text mining in a literature review of urothelial cancer using topic model.

Authors:  Hsuan-Jen Lin; Phillip C-Y Sheu; Jeffrey J P Tsai; Charles C N Wang; Che-Yi Chou
Journal:  BMC Cancer       Date:  2020-05-24       Impact factor: 4.430

9.  The c-MET Network as Novel Prognostic Marker for Predicting Bladder Cancer Patients with an Increased Risk of Developing Aggressive Disease.

Authors:  Young-Won Kim; Seok Joong Yun; Phildu Jeong; Seon-Kyu Kim; Seon-Young Kim; Chunri Yan; Sung Phil Seo; Sang Keun Lee; Jayoung Kim; Wun-Jae Kim
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

Review 10.  Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addiction.

Authors:  Ming-Hai Wang; Ruiwen Zhang; Yong-Qing Zhou; Hang-Ping Yao
Journal:  J Biomed Res       Date:  2013-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.